RecallHawk

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (D...

IMPAX LABS

Summary

FDA approved DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE) by IMPAX LABS. ANDA (Generic) approval (Labeling) on 2024-08-30. CAPSULE, EXTENDED RELEASE, ORAL.

Details

Source

Drug Approval

External ID

ANDA076852-19

Action Date

2024-08-30

Status

Approved

Category

drug

Product Code

ANDA (Generic)

Product Description

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (generic: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE), CAPSULE, EXTENDED RELEASE, ORAL. Application: ANDA076852

Company

Context & Analysis

IMPAX LABS has 6 FDA actions in our database.

Frequently Asked Questions

How often does IMPAX LABS have FDA actions?

IMPAX LABS has 6 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "ANDA076852-19" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions